NO20075831L - Krystallinske faste og amorfe former av (-)- halofenat - Google Patents

Krystallinske faste og amorfe former av (-)- halofenat

Info

Publication number
NO20075831L
NO20075831L NO20075831A NO20075831A NO20075831L NO 20075831 L NO20075831 L NO 20075831L NO 20075831 A NO20075831 A NO 20075831A NO 20075831 A NO20075831 A NO 20075831A NO 20075831 L NO20075831 L NO 20075831L
Authority
NO
Norway
Prior art keywords
crystalline solid
halophenate
amorphous forms
hyperlipidemia
diabetes
Prior art date
Application number
NO20075831A
Other languages
English (en)
Inventor
Eric J Hagen
Edward D Daugs
Jason A Hanko
David H Louks
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of NO20075831L publication Critical patent/NO20075831L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

De krystallinske faste formene kan benyttes i forskjellige farmasøytiske preparater, og er særlig effektive for forebyggelse og/eller behandling av tilstander forbundet med blodlipidavsetning i pattedyr, spesielt de sykdommer som er relatert til type 2 diabetes og hyperlipidemi. Oppfinnelsen angår også en fremgangsmåte for forebyggelse eller behandling av type 2 diabetes og hyperlipidemi i et pattedyr, innbefattende trinnet med administrasjon av en terapeutisk effektiv mengde av krystallinske faste og amorfe former av (-)-halofenat.
NO20075831A 2005-04-20 2007-11-13 Krystallinske faste og amorfe former av (-)- halofenat NO20075831L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67365505P 2005-04-20 2005-04-20
PCT/US2006/015163 WO2006113917A1 (en) 2005-04-20 2006-04-20 Crystalline solid and amorphous forms of (-)- halofenate

Publications (1)

Publication Number Publication Date
NO20075831L true NO20075831L (no) 2008-01-18

Family

ID=37115499

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075831A NO20075831L (no) 2005-04-20 2007-11-13 Krystallinske faste og amorfe former av (-)- halofenat

Country Status (15)

Country Link
US (5) US8203019B2 (no)
EP (1) EP1877362A1 (no)
JP (1) JP2008538570A (no)
KR (1) KR101372271B1 (no)
CN (1) CN101163660A (no)
BR (1) BRPI0610782A2 (no)
CA (1) CA2606279C (no)
CR (1) CR9516A (no)
EA (1) EA200702274A1 (no)
IL (1) IL186664A (no)
MX (1) MX2007012991A (no)
NO (1) NO20075831L (no)
UA (1) UA96571C2 (no)
WO (1) WO2006113917A1 (no)
ZA (1) ZA200709015B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606279C (en) * 2005-04-20 2015-01-06 Metabolex, Inc. Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto
WO2009121940A1 (en) * 2008-04-03 2009-10-08 Janssen Pharmaceutica Nv Process for the preparation of (-)-(4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953490A (en) 1972-07-13 1976-04-27 Merck & Co., Inc. Preparation of (3-trifluoromethylphenoxy)(4-chlorophenyl)acetonitrile
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
CA2606279C (en) * 2005-04-20 2015-01-06 Metabolex, Inc. Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto

Also Published As

Publication number Publication date
WO2006113917A1 (en) 2006-10-26
US8507719B2 (en) 2013-08-13
US20140024852A1 (en) 2014-01-23
CN101163660A (zh) 2008-04-16
AU2006236153A1 (en) 2006-10-26
CA2606279A1 (en) 2006-10-26
EA200702274A1 (ru) 2008-04-28
ZA200709015B (en) 2008-12-31
EP1877362A1 (en) 2008-01-16
UA96571C2 (uk) 2011-11-25
US9845285B2 (en) 2017-12-19
US20120232303A1 (en) 2012-09-13
KR101372271B1 (ko) 2014-03-17
IL186664A0 (en) 2008-01-20
US20150225333A1 (en) 2015-08-13
CR9516A (es) 2008-03-06
BRPI0610782A2 (pt) 2017-01-31
IL186664A (en) 2013-10-31
JP2008538570A (ja) 2008-10-30
CA2606279C (en) 2015-01-06
AU2006236153A2 (en) 2006-10-26
US20080221018A1 (en) 2008-09-11
US20160280636A1 (en) 2016-09-29
KR20070122567A (ko) 2007-12-31
MX2007012991A (es) 2008-03-13
US8993797B2 (en) 2015-03-31
US8203019B2 (en) 2012-06-19
WO2006113917A9 (en) 2008-02-14
US9233914B2 (en) 2016-01-12

Similar Documents

Publication Publication Date Title
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20055892L (no) Karboksylsyrederivater
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
EP2175834B8 (en) Glp-1-fc fusion protein formulation
NO20092527L (no) Prolegemidler, fremgangsmate for fremstilling og anvendelse derav
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2007067504A3 (en) Lactam compounds and methods of using the same
WO2006031293A8 (en) Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
EA200501936A1 (ru) Производные пиридо[2,1-a]изохинолина в качестве ингибиторов dpp-iv
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
NO20054769L (no) Substituerte fenylalkansyrer
BRPI0518898A2 (pt) composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto
DE602006020070D1 (de) Verringerung von schwindel, einer nebenwirkung im zusammenhang mit einer pirfenidon-therapie
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
WO2009035534A3 (en) Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
DK1154795T3 (da) Middel til behandling af diagnosticering af restless legs syndrom
MX2022011535A (es) Composiciones y métodos para tratar o prevenir enfermedades inflamatorias que incluyen diabetes mellitus tipo i y tipo ii y enfermedades de la tiroides.
TW200716146A (en) Method for treating or preventing systemic inflammation in formula-fed infants
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application